Top Stories
CEO Bradley Paddock said the company is ready to reach more patients after recent FDA clearances for seven-day wear and 1-unit dosing.
The Stanford University spinout is initially developing the monitor for adrenal and cardiometabolic diseases.
The positive findings could establish a new standard of care for this untapped patient population.
Proposed venture with Memorial Sloan Kettering would move beyond licensed assays, using MSK oncology data and SOPHiA DDM to develop new diagnostics and companion tools.
The five-year K Pro collaboration builds on a 2021 oncology deal and will focus on AI agents designed for Sanofi’s R&D teams.
Conference News
GE HealthCare to showcase cloud-enabled solutions including Genesis Radiology Workspace and InteleShare at SIIM 2026Enterprise imaging solutions are designed to help improve workflow and productivity,...
New technologies advance scalable library normalization for high-throughput genomics labs and improved amplification accuracy for oncology-focused sequencing workflows where data quality is criticalBo...
BURLINGTON, Mass. and JERUSALEM, June 09, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the ...
SHANGHAI, Jun 9, 2026 - (ACN Newswire) - Hua Medicine ("the Company", stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in ...
Visage releases native Visage 7 | ReportingSAN DIEGO, June 8, 2026 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced it will demo...
